Etravirine (Intelence, TMC125): News & Research
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
- The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from TheBodyPRO.com
- MK-0518 Plus Etravirine? No Problem! (January 5, 2007)
From Project Inform
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
- Tibotec Announces Expanded Access Programme for New NNRTI TMC125 (September 26, 2006)
From aidsmap.com
- Tibotec Pharmaceuticals Ltd. Announces Expanded Access Program for Its Investigational Agent TMC125 (September 25, 2006)
Program will provide early access for eligible HIV-1-infected patients who have limited treatment options.
From Tibotec Pharmaceuticals Ltd.
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
- AIDS Activists Urge Tibotec to Expand Access to TMC125, Show Compassion for HIV Salvage Patients (March 8, 2006)
From Salvage Therapies
- Behind the December 2004 "AIDS Breakthrough" Headlines (December 31, 2004)
Mid-December press reports were exaggerated, but still important; they focus on DAPYs, a promising new family of HIV meds.
In AIDS Treatment News, from AIDS Treatment News
- Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
- Waiting in the Wings: More New Drugs (November/December 2003)
A look at 908, TMC-125 and entry inhibitors in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
- TMC-125: A New NNRTI (March 2002)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a Five-Drug Regimen (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- One Week of Monotherapy with TMC-125, a Novel Highly Potent NNRTI, Produces a Mean 2-Log Reduction in Viral Load in Antiretroviral-Naive, HIV-1-Infected Volunteers (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
